Literature DB >> 16226533

Bilateral blindness from orbital cellulitis caused by community-acquired methicillin-resistant Staphylococcus aureus.

Tina Rutar1, Orin M Zwick, Kimberly P Cockerham, Jonathan C Horton.   

Abstract

PURPOSE: To describe bilateral blindness resulting from infection with community-acquired methicillin-resistant Staphylococcus aureus (MRSA).
DESIGN: Observational case report.
METHODS: A 44-year-old man developed proptosis, ptosis, ophthalmoplegia, and no light perception vision after attempting to lance a nasal pustule. A nasal culture grew MRSA. Imaging showed bilateral orbital cellulitis, pansinusitis, and cavernous sinus thrombosis. The right fundus showed severe ischemia, but the left fundus was essentially normal.
RESULTS: Despite initiation of appropriate antibiotics early in the course of infection, the patient lost sight in both eyes. Surgical drainage of the paranasal sinuses and use of intravenous corticosteroids and heparin led to the resolution of orbital cellulitis.
CONCLUSIONS: MRSA orbital cellulitis can progress to irreversible blindness despite antibiotic treatment. A new, community-acquired clone of this organism has exhibited increased potential for tissue invasion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16226533     DOI: 10.1016/j.ajo.2005.03.076

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  12 in total

1.  [Multiresistant bacteria in ophthalmology].

Authors:  T Ness
Journal:  Ophthalmologe       Date:  2010-04       Impact factor: 1.059

2.  An unusual case of orbital cellulitis due to Panton Valentine Leucocidine producing Staphylococcus aureus.

Authors:  P Alaghband; O Oworu
Journal:  Eye (Lond)       Date:  2012-10-26       Impact factor: 3.775

3.  [Persistent and recurrent skin and soft tissue infections by Staphylococcus aureus. Impact of the small colony-variant (SCV) phenotype and of Panton-Valentine leukocidin (PVL)-positive S. aureus isolates].

Authors:  K Becker; A Kriegeskorte; C Sunderkötter; B Löffler; C von Eiff
Journal:  Hautarzt       Date:  2014-01       Impact factor: 0.751

Review 4.  Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic.

Authors:  Michael Z David; Robert S Daum
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

5.  Suppression of innate immunity by a nasal carriage strain of Staphylococcus aureus increases its colonization on nasal epithelium.

Authors:  Gerry A Quinn; Alexander M Cole
Journal:  Immunology       Date:  2007-04-30       Impact factor: 7.397

6.  Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcus aureus strains.

Authors:  Saichi Hoshi; Ken Kikuchi; Takashi Sasaki; Chie Sotozono; Shigeru Kinoshita; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2008-05-19       Impact factor: 5.191

Review 7.  Chloramphenicol Resurrected: A Journey from Antibiotic Resistance in Eye Infections to Biofilm and Ocular Microbiota.

Authors:  Drago Lorenzo
Journal:  Microorganisms       Date:  2019-08-21

8.  Hospital-Associated Multidrug-Resistant MRSA Lineages Are Trophic to the Ocular Surface and Cause Severe Microbial Keratitis.

Authors:  Paulo J M Bispo; Lawson Ung; James Chodosh; Michael S Gilmore
Journal:  Front Public Health       Date:  2020-06-03

9.  Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics.

Authors:  Joseph S Bertino
Journal:  Clin Ophthalmol       Date:  2009-09-24

10.  Periorbital infections and conjunctivitis due to Panton-Valentine Leukocidin (PVL) positive Staphylococcus aureus in children.

Authors:  Pia-Alice Hoppe; Leif G Hanitsch; Rasmus Leistner; Michaela Niebank; Christoph Bührer; Horst von Bernuth; Renate Krüger
Journal:  BMC Infect Dis       Date:  2018-08-06       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.